Adhesion molecules as targets for the treatment of neoplastic diseases

Current Pharmaceutical Design

Volumn 12, Issue 22, 2006, Pages 2849-2861

  Syrigos, Konstantinos N ^a   Kararyiannakis, Anastasios J ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

CEA; Cell adhesion; E cadherin catenin complex; Integrins; Selectins; Targeted therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALICAFORSEN; AMYGDALIN; AVIDIN; BETA CATENIN; BIOLOGICAL MARKER; BIOTIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULE; CETUXIMAB; CILENGITIDE; CORTICOSTEROID; CYTOTOXIC AGENT; ENDOTOXIN; INDIUM 111; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; IODINE 131; MATUZUMAB; MONOCLONAL ANTIBODY LM 609; NONSTEROID ANTIINFLAMMATORY AGENT; PANITUMUMAB; PSEUDOMONAS ENDOTOXIN; RICIN A; SAPORIN; STREPTAVIDIN; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL ADHESION; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SPECIFICITY; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; MEDICINE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TISSUE INJURY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 33746881011     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777947759     Document Type: Review

References (125)

1. Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Sekara E, Michail P, et al. Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients. Am J Gastroenterol 2003; 98: 478-85.
2. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A casual role of E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190-3.
3. Coman DR. Decreased mutual adhesiveness, a property of cells from squamous cell carcinomas. Cancer Res 1944; 4: 625-9.
4. Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, et al. Senim levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001; 37: 2392-7.
5. Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, Karatzas G. E-cadherin expression as a differentiation marker in gastric cancer. Hepatogastroenterology 1998; 45: 2437-42.
6. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993; 5: 806-11.
7. Harrington KJ, Syrigos KN. The role of E-cadherin-catenin complex: more than an intercellular glue? Ann Surg Oncol 2000; 7: 783-8.
8. Rosales C, Juliano RL. Signal transduction by cell adhesion receptors in leukocytes. J Leukoc Biol 1995; 57:189-98.
9. Rosales C, O'Brien V, Kornberg L, Juliano RL. Signal transduction by cell adhesion receptors. Biochim Biophy Acta 1995; 1242: 77-98.
10. Hynes RO, Lander AD. Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell 1992; 68: 303-22.
11. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996; 84:345-57.
12. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Ann Rev Biochem 1990; 59: 237-52.
13. Loftus JC, Smith JW, Ginsberg ME. Integrin-mediated cell adhesion: the extracellular face. J Biol Chem 1994; 269: 25235-8.
14. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91: 2645-57.
15. Shattil SJ, Ginsberg MH. Integrin signaling in vascular biology. J Clin Invest 1997; 100: 1-5.
16. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994: 76: 301-14.
17. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 1988; 102: 639-55.
18. Levine E, Lee CH, Kintner C, Gumbiner BM. Selective disruption of E-cadherin ftmction in early Xenopus embryos by a dominant negative mutant. Development 1994; 120: 901-9.
19. Dufour S, Saint-Jeannet JP, Broders F, Wedlich D, Thiery JP. Differential perturbations in the morphogenesis of anterior structures induced by overexpression of truncated XB- and N-cadherins in Xenopus embryos. J Cell Biol 1994; 127: 521-35.
20. Peifer M, Orsulic S, Sweeten D, Wieschaus E. A role for the Drosophila segment polarity gene armadillo in cell adhesion and cytoskeletal integrity during oogenesis. Development 1993; 118: 1191-207.
21. Heasman J, Crawford A, Goldstone V, Gamer-Hamrick P, Gumbiner B, McCrea P, et al. Overexpression of cadberins and underexpression of β-catenin inhibit dorsal mesoderm induction in early Xenopus embryos. Cell 1994; 79: 791-803.
22. McCrea PD, Brieher WM, Gumbiner BM. Induction of a secondary body axis in Xenopus by antibodies to beta-catenin. J Cell Biol 1993; 123: 477-84.
23. Funayama N, Fagotto F, McCrea P, Gumbiner BM. Embryonic axis induction by the armadillo repeat domain of beta-catenin: evidence for intracellular signaling. J Cell Biol 1995; 128: 959-68.
24. Karnovsky A, Klymkowsky MW. Anterior axis duplication in Xenopus induced by the over-expression of the cadherin-binding protein plakoglobin. Proc Natl Acad Sci USA 1995; 92: 4522-6.
25. Larne L, Ohsugi M, Hirchenhain J, Kemler R. E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci USA 1994; 91: 8263-7.
26. Riethmacher D, Brinkmann V, Birchmeier C. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc Natl Acad Sci USA 1995; 92: 855-9.
27. Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, Kemler R. Lack of beta-catenin affects mouse development at gastrulation. Development 1995; 121: 3529-37.
28. Hermiston ML, Gordon JI. In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death. J Cell Biol 1995; 129: 499-506.
29. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270: 1203-7.
30. Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev 1996; 10: 985-96.
31. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-101.
32. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993; 9: 317-21.
33. Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 1994; 125: 1327-40.
34. Syrigos KN, Harrington KJ, Pignatelli M. Role of adhesion molecules in bladder cancer: an important part of the jigsaw. Urology 1999; 53: 428-34.
35. Hoschuetzky H, Aberle H, Kemler R. β-Catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994; 127: 1375-80.
36. Ochiai A, Akimoto S, Kanai Y, Shibata T, Oyarna T, Hirohashi S. c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun 1994; 205: 73-8.
37. Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, et al. c-erbB-2 gene product directly associates with β-catenin and plakoglobin. Biochem Biophys Res Commun, 1995; 209: 1067-72.
38. Rubinfeld B, Souza B, Albert I, Müller O, Chamberlain SH, Masiarz FR, et al. Association of the APC gene product with β-catenin. Science 1993; 262: 1731-4.
39. So L-K, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993; 262: 1734-7.
40. Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Oku N, Miyazawa K, et al. Tyrosine phosphorylation of β-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes Commun 1994; 1: 295-305.
41. Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Miyazawa K, Kitamura N, et al. Association of p120, a tyrosine kinase substrate, with E-cadherin/ catenin complexes. J Cell Biol 1995; 128: 949-57.
42. Shiozaki H, Kadowaki T, Doki Y, Inoue M, Tamura S, Oka H, et al. Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br J Cancer 1995; 71: 250-8.
43. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-7.
44. Aust DE, Terdiman JP, Willenbucher RF, Chew K, Ferrell L, Florendo C, et al. Altered distribution of β-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod Pathol 2001; 14: 29-39.
45. Tamura G, Maesawa C, Suzuki Y, Tamada H, Satoh M, Ogasawara S, et al. Mutations of the APC gene occur during early stages of gastric adenoma development. Cancer Res 1994; 54: 1149-51.
46. Powell SM, Papadopoulos N, Kinzler KW, Smolinski KN; Meltzer SJ. APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology 1994; 107: 1759-63.
47. Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, et al. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 3122-7.
48. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995; 92: 3046-50.
49. Hülsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with β-catenin and the cytoskeleton. J Cell Biol 1994; 127: 2061-9.
50. Rubinfeld B, Souza B, Albert I, Munemitsu S, Polakis P. The APC protein and E-cadherin form similar but independent complexes with α-catenin, β-catenin, and plakoglobin. J Biol Chem 1995; 270: 5549-55.
51. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997; 275: 1787-90.
52. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-2.
53. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996; 382: 638-42.
54. Karayiannakis AJ, Syrigos KN, Savva A, Polychronidis A, Karatzas G, Simopoulos C. Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy. Surg Endosc 2002; 16: 1551-4.
55. Hinck L, Nelson WJ, Papkoff J. Wnt-1 modulates cell-cell adhesion in mammalian cells by stabilizing beta-catenin binding to the cell adhesion protein cadherin. J Cell Biol 1994; 124: 729-41.
56. Nathke IS, Hinck L, Swedlow JR, Papkoff J, Nelson WJ. Defining interactions and distributions of cadherin and catenin complexes in polarized epithelia] cells. J Cell Biol 1994; 125: 1341-52.
57. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003; 20: 203-13.
58. Sung V, Stubbs JT, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998; 176: 482-94.
59. Taverna D, Ullman-Cullere M, Rayburn H, Bronson RT, Hynes RO. A test of the role of alpha5 integrin/fibronectin interactions in tumorigenesis. Cancer Res 1998; 58: 848-53.
60. Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D, et al. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vase Biol 2002; 22: 927-33.
61. LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer 2002; 100: 2-8.
62. Hubbard AK, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radical Biol Med 2000; 28:1379-86.
63. Jiang Z, Woda BA, Savas L, Fraire AE. Expression of ICAM-1, VCAM-1, and LFA-1 in adenocarcinoma of lung with observations on the expression of these adhesion molecules in non neoplastic lung tissue. Mod Pathol 1998; 11: 1189-92.
64. Pignatelli M, Vessey CJ. Adhesion molecules: novel molecular tools in tumor pathology. Hum Pathol 1994: 25: 849-56.
65. Smythe WR, Williams JP, Wheelock MJ, Johnson KR, Kaiser LR, Albelda SM. Cadberin and catenin expression in normal human bronchia epithelium and non-small cell lung cancer. Lung Cancer 1999; 24: 157-68.
66. Lim SC, Jang IG, Kim YC, Park KO. The role of E-cadherin expression in non-small cell lung cancer. J Korean Med Sc 2000; 15: 501-6.
67. Staal-van den Brekel AJ, Thunnissen FB, Buurman WA, Wouters EF. Expression of E-selectin, intercellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1) in non-small cell lung carcinoma. Virchows Arch 1996; 428: 21-7.
68. Lynch DF Jr, Hassen W, Clements MA, Schellhammer PF, Wright GL Jr. Seram levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate 1997; 32: 214-20.
69. Satoh M, Numahata K, Kawamura S, Saito S, Orikasa S. Lack of selectin-dependent adhesion in prostate cancer cells expressing sialyl Le(x). Int J Urol 1998; 5: 96-91.
70. Wictrzyk J, Opolski A, Madej J, Laskowska A, Radzikowski C, Ugorski M. Metastatic potential of human uroepithelial cancer cells is not dependent on their adhesion to E-selectin. Anticancer Res 2000; 20: 913-6.
71. Okegawa T, Li Y, Pong RC, Hsieh JT. Cell adhesion proteins as tumor suppressors. J Urol 2002; 167: 1836-43.
72. Tynan K, Olsen A, Trask B, de Jong P, Thompson J, Zimmermann W, et al. Assembly and analysis of cosmid contigs in the CEA-gene family region of human chromosome 19, Nucleic Acids Res 1992; 20: 1629-36.
73. Williams AF, Barclay AN. The immunoglobulin superfamily - domains for cell surface recognition. Annu Rev Inummol 1988; 6: 381-405.
74. Thompson J, Zimmerman W. The carcinoembryonic gene family: structure, expression and evolution. Tumor Biol 1988; 9: 63-83.
75. Leusch HG, Hefta SA, Drzeniek Z, Hummel K, Markos-Pusztai Z, Wagener C. Escherichia coli of human origin binds to carcinoembryonic antigen (CEA) and non-specific crossreacting antigen (NCA). FEBS Lett 1990; 261: 405-9.
76. Konstadoulakis MM, Syrigos KN, Albanopoulos C, Mayers G, Golematis B. The presence of anfi-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies. J Clin Immunol 1994; 14: 310-3.
77. Zbar AP, Lemoine NR, Wadhwa M, Thomas H, Snary D, Kmiot WA. Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target. Br J Cancer 1998; 77: 683-93.
78. Petruzzelli L, Takami M, Humes HD. Structure and function of cell adhesion molecules. Am J Med 1999; 106: 467-76.
79. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90: 2312-6.
80. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. Senim levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patient. Anticancer Res 2001; 21: 1355-8.
81. Salgami EV, Efstathiou SP, Vlachakis V, Sekara EV, Syrigos KN, Roussou PP. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma. Haematologia (Budap) 2002; 32: 377-87.
82. Matarrese P, Giandomenico V, Fiorucci G, Rivabene R, Straface E, Romeo G, et al. Antiproliferative activity of interferon alpha and refinoic acid in SiHa carcinoma cells: the role of cell adhesion. Int J Cancer 1998; 76: 531-40.
83. Szekanecz Z, Koch AE. Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Curr Opin Pharmacol 2004; 4: 423-8.
84. Karayiannakis AJ, Syrigos KN, Polychronidis A, Simopoulos C. Expression patterns of α-, β- and γ-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. Anticancer Res 2001; 21: 4127-34.
85. Karatzas G, Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, Simatos G, et al. Expression patterns of the E-cadherin-catenin cell-cell adhesion complex in gastric cancer. Hepatogastroenterology 2000; 47:1465-9.
86. Karayiannakis AJ, Syrigos KN, Alexiou D, Kalahanis N, Rosenberg T, Bastounis E, et al. Expression patterns of the novel catenin p120cas in gastrointestinal cancers. Anticancer Res 1999; 19: 4401-5.
87. Seery JP, Syrigos KN, Karayiannakis AJ, Valizadeh A, Pignatelli M. Abnormal expression of the E-cadherin-catenin complex in dysplastic Barrett's oesophagus. Acta Oncol 1999; 38: 945-8.
88. Karatzas G, Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, Riza F, et al. E-cadherin expression correlates with tumor differentiation in colorectal cancer. Hepatogastroenterology 1999; 46: 232-5.
89. Syrigos KN, Salgami E, Karayiannakis AJ, Katirtzoglou N, Sekara E, Roussou P. Prognostic significance of soluble adhesion molecules in Hodgkin's disease. Anticancer Res 2004; 24: 1243-7.
90. Syrigos KN, Harrington KJ, Karayiannakis AJ, Baibas N, Katirtzoglou N, Roussou P. Circulating soluble E-cadherin levels are of prognostic significance in patients with multiple myeloma. Anticancer Res 2004; 24: 2027-31.
91. Haass NK, Smalley KS, Herlyn M. The role of altered cell-cell communication in melanoma progression. J Mol Histol 2004; 35: 309-18.
92. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000; 87: 992-1005.
93. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-19.
94. Cavallaro U. N-cadherin as an invasion promoter: a novel target for antitumor therapy? Curr Opin Investig Drugs 2004; 5: 1274-8.
95. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherm mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-85.
96. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat Med 2002; 8: 27-34.
97. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell 1998, 95: 507-19.
98. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004; 90: 561-5.
99. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003; 4: 722-31.
100. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M. Inhibition of the alpha-v integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002; 86: 788-95.
101. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, et al. αv-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98: 690-7.
102. Burkhart DJ, Kalet BT, Coleman MP, Post GC, Koch TH. Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Mol Cancer Ther 2004; 3: 1593-604.
103. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 2004; 40: 228-30.
104. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumors. Eur J Cancer 2003; 39: 917-26.
105. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62: 4263-72.
106. MacDonald TJ, Ladisch S. Antisense to integrin αv inhibits growth and induces apoptosis in medulloblastoma cells. Anticancer Res 2001; 21: 3785-91.
107. Tucker GC. Inhibitors of integrins. Curr Opin Pharmacol 2002; 2: 394-402.
108. Syrigos KN, Karayiannakis AJ, Zbar A. Mucins as immunogenic targets in cancer. Anticancer Res 1999; 19: 5239-44.
109. Syrigos KN, Deonarian DP, Epenetos AA. Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer. Hybridoma 1999; 18: 219-24.
110. Sarobe P, Huarte E, Lasarte JJ, Borras-Cuesta F. Carcinoembryonic antigen as a target to induce anti-tumor immune responses. Curr Cancer Drug Targets 2004; 4: 443-54.
111. Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996; 43: 127-34.
112. Ragupathi G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 1996; 43: 152-7.
113. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993; 177: 989-98.
114. Conry RM, LoBuglio AF, Curiel DT. Polynucleotide mediated immunization therapy of cancer. Semin Oncol 1996; 23: 135-47.
115. Kaufman H, Schlom J, Kantor J. A recombinant Vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991; 48: 900-7.
116. Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, et al. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther 1995; 2: 33-8.
117. Thompson JA, Eades-Perner AM, Ditter M, Muller WJ, Zimmermann W. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy. Int J Cancer 1997; 72:197-202.
118. Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, et al. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 2004; 64: 4995-5003.
119. Sanchez-Madrid F, Gonzalez-Amaro R. Drugs, inflammation and cell adhesion receptors. Expert Opin Pharmacother 2001; 2: 3-17.
120. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002; 23: 482-6.
121. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998; 124: 225-31.
122. Clapper ML, Coudry J, Chang WC. β-catenin-mediated signaling: a molecular target for early chemopreventive intervention. Mutat Res 2004; 555: 97-105.
123. Bazan-Socha S, Bukiej A, Marcinkiewicz C, Musial J. Integrins in pulmonary inflammatory diseases. Curr Pharm Des 2005; 11(7): 893-901.
124. Danen EH. Integrins: regulators of tissue function and cancer progression. Curr Pharm Des 2005; 11(7): 881-91.
125. Paulhe F, Manenti S, Ysebaert L, Betous R, Sultan P, Racaud-Sultan C. Integrin function and signaling as pharmacological targets in cardiovascular diseases and in cancer. Curr Pharm Des 2005; 11(16): 2119-34.